Lazard Asset Management
APLS

Lazard Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Lazard Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,024
Closed -$17K – 1842
2025
Q2 		$17K Sell
1,024
-2,529
-71% -$46.8K ﹤0.01% 2135
2025
Q1 		$77K Buy
+3,553
New +$98.2K ﹤0.01% 1880
2024
Q4 		– Sell
-3,202
Closed -$92K – 2271
2024
Q3 		$92K Sell
3,202
-2,993
-48% -$111K ﹤0.01% 1793
2024
Q2 		$237K Buy
6,195
+3,387
+121% +$153K ﹤0.01% 1506
2024
Q1 		$165K Sell
2,808
-79,703
-97% -$5.08M ﹤0.01% 1371
2023
Q4 		$4.94M Sell
82,511
-33,378
-29% -$1.69M 0.01% 686
2023
Q3 		$4.41M Buy
115,889
+104,805
+946% +$4.6M 0.01% 724
2023
Q2 		$1.01M Sell
11,084
-24,220
-69% -$2.09M ﹤0.01% 989
2023
Q1 		$2.33M Sell
35,304
-49,516
-58% -$2.86M ﹤0.01% 888
2022
Q4 		$4.39M Buy
84,820
+38,724
+84% +$2.05M 0.01% 744
2022
Q3 		$3.15M Buy
46,096
+34,053
+283% +$2.02M ﹤0.01% 799
2022
Q2 		$544K Buy
12,043
+9,360
+349% +$427K ﹤0.01% 1097
2022
Q1 		$136K Buy
+2,683
New +$118K ﹤0.01% 1322
2021
Q4 		– Sell
-1,236
Closed -$40K – 2278
2021
Q3 		$40K Buy
+1,236
New +$69.4K ﹤0.01% 1783
2021
Q2 		– Sell
-1,324
Closed -$56K – 1952
2021
Q1 		$56K Sell
1,324
-11,865
-90% -$561K ﹤0.01% 1385
2020
Q4 		$754K Buy
+13,189
New +$558K ﹤0.01% 925
2019
Q4 		– Sell
-52,655
Closed -$1.27M – 1525
2019
Q3 		$1.27M Buy
+52,655
New +$1.45M ﹤0.01% 721

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Lazard Asset Management's APLS Position: Q3 2025 in Review

Lazard Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 1,024 shares — an estimated $17K sold.

Lazard Asset Management first reported a position in APLS in Q3 2019 and held it in 17 quarters. The position peaked at $4.94M in Q4 2023. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Lazard Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,024 Apellis Pharmaceuticals shares in Q3 2025, an estimated $17K.
  • Lazard Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 17 quarters.
  • Lazard Asset Management's Apellis Pharmaceuticals position peaked at $4.94M in Q4 2023.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.